| Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study. | |
| | |
MedLine Citation:
|
PMID: 19852154 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND AND AIM OF THE STUDY: Ergot-derived dopamine agonists (DAs) are used in the treatment of Parkinson's disease, but may be associated with valvular heart disease and pulmonary hypertension. The study aim was to examine changes in cardiovascular abnormalities after the discontinuation or continuation of anti-parkinson treatment. METHODS: Parkinson patients treated with either ergot-derived (n = 32) or non-ergot-derived (n = 8) DAs who had been diagnosed with valvular abnormalities or pulmonary hypertension, were included in this one-year follow up study. After an initial echocardiography, five patients continued ergot-derived DA treatment, while the remaining 35 either changed (n = 27) or continued (n = 8) non-ergot-derived DA treatment. The patients were followed up after a mean of 14 months (range: 12-18 months). Changes in the severity of valve disease and pulmonary hypertension were evaluated by an analysis of digitally stored echocardiograms. The recordings were performed blinded to medical treatment, while the analyses were blinded to both the medical treatment and the timing of image acquisition. RESULTS: Follow up revealed the risk of worsening cardiovascular abnormalities to be 60% in patients who continued ergot-derived DA treatment, compared to 14% in those who changed to, or continued with, non-ergot-derived DA medication (p < 0.05). Overall, patients who changed from ergot-derived to non-ergot-derived DAs did not exhibit any significant worsening or improvement of their valve abnormality, although the pulmonary artery pressure (PAP) fell from 26 +/- 12 mmHg to 22 +/- 8 mmHg at follow up (p < 0.005). CONCLUSION: At one year after discontinuation of ergot-derived DAs, a mild but statistically significant reduction in PAP was detected. Overall, valvular regurgitation remained without definite worsening or improvement in these patients. Among patients who continued ergot-derived DAs despite a cardiovascular abnormality, the follow-up indicated an increased risk of worsening. |
| | |
Authors:
|
Vibeke G Rasmussen; Steen H Poulsen; Erik Dupont; Karen Østergaard; Gholamhossein Safikhany; Henrik Egeblad |
Related Documents
:
|
1545014 - Aortic anastomotic pseudoaneurysms: us, ct, mr, and angiography. 17045674 - Sorin stentless pericardial valve versus carpentier-edwards perimount pericardial biopr... 12227714 - Cardiovascular involvement in behçet's disease. 17202454 - Valvular heart disease and the use of dopamine agonists for parkinson's disease. 20735714 - Sleep disordered breathing and arrhythmia burden in pacemaker recipients. 21191314 - Serum thyroglobulin predicts thyroid remnant ablation failure with 30 mci iodine-131 tr... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: The Journal of heart valve disease Volume: 18 ISSN: 0966-8519 ISO Abbreviation: J. Heart Valve Dis. Publication Date: 2009 Jul |
Date Detail:
|
Created Date: 2009-10-26 Completed Date: 2009-12-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9312096 Medline TA: J Heart Valve Dis Country: England |
Other Details:
|
Languages: eng Pagination: 463-9 Citation Subset: IM |
Affiliation:
|
Department of Cardiology, Aarhus University Hospital, Skejby, Aarhus, Denmark. vibeke.guldbrand@ki.au.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Dopamine Agonists / adverse effects* Ergot Alkaloids / adverse effects* Female Heart Valve Diseases / chemically induced*, epidemiology, ultrasonography Humans Hypertension, Pulmonary / chemically induced, epidemiology Male Middle Aged Mitral Valve / ultrasonography Parkinson Disease / drug therapy*, epidemiology, ultrasonography |
| Chemical | |
Reg. No./Substance:
|
0/Dopamine Agonists; 0/Ergot Alkaloids |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Screening coronary angiography prior to surgery in rheumatic valvular heart disease: a study of 2,18...
Next Document: Different directions for the biological evaluation of biomaterials.